We retrospectively assessed the clinical uses and results of sildenafil in the treatment of erectile dysfunction (ED) in daily clinical practice from a cohort of 1658 subjects at a multispeciality medical center from 1999 to 2001 through a chart review, mailed questionnaire and telephone interview. The overall follow-up rate was 77.8% (1290/1658). The mean age was 63.8 y and ED duration was 3.4 y, and 44.6% of them had one or more concomitant conditions. The mean score of the International Index of Erectile Function erectile function domain was 12.7 in 314 nonselective subjects, and 75% of them had moderate to severe ED. The average number of purchase-visits and tablets of sildenafil purchased was 2.27 and 10.8 per person, respectively, and the prescription refill rate was 58.6%. Urology accounts for 91.4% of the specialties of prescribers. The response rate was 72.0%, which was significantly lower in subjects with diabetes, ischemic heart disease and following radical pelvic surgery than those without. Subjects with psychogenic etiology had the highest response rate, while those following radical pelvic surgery the lowest. Of the nonresponders, 67% did not try the maximum dose of 100 mg and 71.1% bought no more than four tablets. Adverse events were reported in 20.1% of the subjects. No one discontinued the treatment because of the adverse events. Mortality occurred in 17 subjects and none was considered related to sildenafil use. In conclusion, sildenafil was effective and safe in the treatment of ED in clinical practice. Compared with clinical trials or prospective clinical practice based studies, lack of dose titration, less follow-up visits and inadequate attempts before giving up were the main shortfalls in daily practice.
Introduction
Sildenafil citrate (Viagrat) is a potent inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) that enhances penile erection to sexual stimulation. 1 Since its introduction in 1998, sildenafil has gained worldwide acceptance as the first-line treatment of erectile dysfunction (ED) of organic, psychogenic or mixed etiology. 2 To date, numerous publications have advocated its efficacy and safety profiles in the treatment of ED in the general population as well as in those with specific diseases such as diabetes, hypertension, uremia, spinal cord injury, depression and following radical prostatectomy. Sildenafil has several distinct characteristics that are necessary for sexual stimulation to take effect, only taken as needed, dose titration and times of attempt affecting the response rate. 2, 3 A thorough education to patients and regular follow-up are important to achieve its optimal use.
Data from randomized, double-blind, placebocontrolled trials provided the most accurate assessment of causality, but the participants were restricted by specific inclusion and exclusion criteria. Clinical practice based studies reflected more routine practice, whereas most of them were conducted prospectively under a controlled condition. The actual experience in clinical practice to reflect a real world sounds precious and interesting. We retrospectively evaluated the use of sildenafil and its efficacy and safety, utilizing a cohort of patients from a multispecialty medical center based practice.
Materials and methods
We used the computer system at our institution to search for subjects who had ED and received prescriptions of sildenafil in outpatient settings from March 1999, when the Drug Administration of Taiwan approved the release of Viagrat, to the end of 2001. Their demographic data, including age, ED duration, concomitant conditions, number of purchase-visits and tablets of sildenafil purchased, the physician specialty of prescribers and the clinical results were recorded first through a chart review in all the subjects. Subjects who replied ''yes'' to the global efficacy question (GEQ) ''With Viagrat treatment, did you have successful sexual intercourse?'' were defined as sildenafil responders, while the remaining as nonresponders. The records of clinical results comprised the response to the GEQ, self-reported adverse events (AEs), the optimal responding dose in responders and the maximum tried dose in nonresponders. For subjects with incomplete data, a mailed questionnaire was sent to collect information, including concomitant conditions and clinical results. For those with wrong addresses and invalid or no return of questionnaires, telephone interviews about the same questions were conducted as the last resort by a single interviewer, Dr BP Jiann.
A Chinese version of the International Index of Erectile Function (IIEF) 4 erectile function domain composed of Q1-Q5 and Q15 of IIEF was applied to evaluate the baseline status of ED in 314 nonselective subjects before treatment. 
Results
From 1999 to 2001, a total of 1658 subjects had sildenafil treatment for ED at our institution. Their demographic data are listed in Table 1 . The median score of IIEF erectile function domain was 13, and 75% of 314 subjects assessed were considered to have moderate or severe ED as their scores were below 17. One or more of the listed comorbidities were found in 740 (44.6%) subjects, with hypertension and diabetes being the two most common conditions. An association with malignancy was recorded in 43 (2.6%) subjects, including malignancy of colon in 10, prostate in nine, rectum in five, bladder in four, kidney in three, lung in three and others in nine. Seven subjects had a surgical history of penile implants, which had been removed in five and preserved in two. The mean follow-up duration in the chart review group was 9.5 months (0.2-33.5) and the mean interval from the first visit till the results were obtained was 29.6 months (9.1-42.1) in the mailed questionnaire group and 32.5 months (11.1-44.8) in the telephone interview group.
A total of 96 (7.4%) subjects denied ever taking sildenafil. The reason for never using sidenafil was the fear of side effects in 39 cases (40.6%), no chance to use in 15 (15.6%), body disabled in five (5.2%), buying it for friends in two (2.1%) and unspecified in 35 (36.5%).
After excluding 96 subjects who never took sildenafil after purchase and seven subjects with a history of penile implants from efficacy calculation, a total of 855 in 1187 subjects (72.0%) were sildenafil responders. The response rates in the chart review, mailed questionnaire and telephone interview groups were 80.9% (594/734), 60.2% (160/266) and 54.0% (101/187), respectively.
Dose information was not available in 11 responders and 21 nonresponders. The distribution of the optimal responding dose of the sildenafil in 844 responders and maximum tried dose in 311 nonresponders is listed in Table 3 . Of the responders, 72% required 50 mg or less of sildenafil to achieve a successful sexual intercourse. Of the nonresponders, 67% did not try the maximum dose of 100 mg.
A comparison of age, ED duration, total number of purchase-visits and severity of ED between responders and nonresponders is shown in Table 4 . Among them, the information on ED duration was available in 871 subjects and baseline IIEF erectile function domain score in 267. On average, the responders were 3 y younger in age, 1 y shorter in ED duration and had 1.8 more of purchase-visits than nonresponders. Of 311 nonresponders, 71.1% bought no more than four tablets of sildenafil. The overall prescription refill rate was 58.6% (972/1658), with 66.2% in responders and 26.5% in nonresponders. Although there was no statistically significant difference in response rate among various ED severities, there was a trend to show the milder severity of ED, the better the response to sildenafil.
The univariate analysis with respect to the response rate to sildenafil based on different comorbidities showed that significantly lower response rate existed in subjects with diabetes, ischemic heart disease and following radical pelvic surgery than those without (Table 5) . Subjects with a psychogenic etiology had the highest response rate (82.4%) while subjects following radical pelvic surgery the lowest (30.8%) as compared among the groups with comorbidity.
In 1171 subjects whose information on AE was available, 20.1% (235) reported one or more kinds of AEs. The incidence of AE is listed in Table 6 . Flushing (13.5%) is the most common AE, followed by palpitation (3.2%), headache (2.6%) and altered vision (2.6%). No one discontinued the treatment because of AE. 
Concomitant prescriptions of nitrate and sildenafil were recorded in 11 subjects. A total of eight subjects had nitrate in regular or taken-as-needed use, but sildenafil was inadvertently prescribed to them; three subjects had new nitrate prescriptions within 1 month after sildenafil purchasing. Further investigation into their uses revealed that four subjects had taken sildenafil while three never did, and for the remaining four subjects this was not known. No cardiovascular event occurred in all of them.
During follow-up, 17 subjects (1.0%) expired. The cause of death, age at death and interval from purchase to death are shown in Table 7 . Based on the nature of the cause and long interval, none of their deaths was considered related to sildenafil. The only concern was an 81-y-old subject who lived alone and was found dead by his neighbor 1 month after sildenafil purchase. The cause of death was considered as unknown. (2) 62 (44), 86 (12) Traffic accident (2) 71 (12), 70 (10) Liver cirrhosis (1) 37 (5) Unknown (1) 81 (1) 3-year Viagra in clinical practice B-P Jiann et al
Discussion
While most studies reported the response rate of sildenafil to fall around 70%, a wide range, varying from 86 to 57%, [5] [6] [7] [8] [9] [10] [11] of response rate has been observed in clinical practice settings. This wide range implies the fact that the response rate is affected by many factors: diversities of study subjects, duration of treatment period, number of follow-up visits, definition of response to treatment and level of return rate.
Subjects with malignancy, alcoholism, Peyronie's disease or penile implants were generally excluded from the earlier clinical trials. As sildenafil provides a noninvasive and an easy mode of therapy and none of the characteristics could be used to predict its absolute failure, 10 sildenafil should be tried first on them, even though a lower response rate would be expected.
In our study, we found that the chart review group had the highest response rate (80.9%), followed by the mailed questionnaire (60.2%) and telephone interview group (54.0%). The discrepancy seemed to indicate that subjects with poor response were less likely to follow up or to reply to the questionnaire. Adjusting the response rate by taking into consideration the group who were lost to follow-up, especially when this proportion of subjects is large, is necessary to correct this possible bias. In our study, 21.4% of subjects were lost to follow-up. Supposing that the response rate was as poor as that in the telephone interviewed group, the response rate in our study population would be adjusted from the original 72.0% to 67.9%.
Owing to the limitation for follow-up in a retrospective study, treatment efficacy was assessed by answering ''yes'' or ''no'' to one simple GEQ, which might be considered too simple to reflect the ''wax and wane'' character of individual sexual performance. Nevertheless, our response rate was comparable with other studies. In one flexible-dose study, erections sufficient for intercourse on most to all occasions were achieved by 69% of sildenafil recipients vs 23% of placebo recipients. 12 In a placebo-controlled study conducted in Taiwan, the success rate of sexual intercourse was 62% and the response rate based on their answers to GEQ, which assessed the improvement in penile erection, reached 88%. 13 It was demonstrated that escalating the dose and having more attempts would improve the response rate of sildenafil. 2, 3 Several shortfalls emerged from our findings in daily practice: 67% of nonresponders did not try the maximum dose of 100 mg, 71.1% of nonresponders purchased no more than four tablets and the prescription refill rate of nonresponders was only 26.5%. If they had tried the maximum dose, made more attempts and received a regular follow-up, they might have been benefited from sildenafil treatment.
Although sildenafil is effective, the discontinuation rate is high as claimed by many urologists that 65% of the subjects had never been seen again.
14 In our series, the refill rate was 58.6% for all subjects and was just 66.2% even for the responders. Several possible reasons were attributed to this low refill rate: more time consuming and higher cost in obtaining refill at the medical center than at the local clinic or over-the-counter drugstore, financial stress, patient and partner motivation, getting old, progression of underlying disease or just for curiosity. It will be interesting to conduct a further investigation into this.
Our study confirmed the previous reports that subjects with psychogenic etiology whowed the best response rate, followed by those with vasculogenic and then with neurogenic etiology. It indicates that the effect of sildenafil is more dependent on adequate nerve supply to the corpora than blood flow. 10 Findings from the same study suggested that treatment satisfaction correlated with ED severity (41% in severe ED, 78% in moderate and 100% in mild). 10 There is a similar trend to show that the milder the severity of ED, the better the response to sildenafil, in spite of not being statistically significant (P ¼ 0.70) in the present study.
The common AEs associated with sildenafil are headache, flushing, dyspepsia, nasal stuffiness and altered vision, 15 reflecting the abundant distribution of PDE5 in systemic vasculature, gastro-esophageal sphincter and the nasal mucosa and also a crossreaction to PDE6 in the retina. 16 The reported incidence of AE to sildenafil ranged from 63 to 20%. 17 The methodology of data collection and the distribution of dosing in a study exert a significant impact on the reported incidence. Specific and directed questions asked regarding AE in contrast to open-ended questions resulted in a higher reporting of AE. 18, 19 This phenomenon also implied the fact that the AE was mild in nature. It is also noted that the incidence of AE correlated with the dosing of sildenafil. 2, 18 In a prospective clinical practice based study of 2816 Hispanic, 5 the total incidence of AE was almost the same as ours (20%). Morales et al 15 analyzed the safety and toleration data from 18 phase II/III studies and 10 long-term open-labeled studies of sildenafil in the treatment of ED, and pointed out that the most common AE and leading cause of discontinuation of treatment was headache. It is interesting to note that the Chinese in Taiwan seemed to have a relatively lower incidence of headache both in the trial 13 and the present study than other races (Table 6 ).
In the current study, 3% (39/1290) of the subjects did not use sildenafil after obtaining it on account of fear of AE. A previous report demonstrated that 11% of the subjects after purchase dared not use it because of the same reason, especially death. 8 This safety concern has stemmed primarily from sporadic reports of AE published in the literature and 3-year Viagra in clinical practice B-P Jiann et al sensationalized by the media. 17 Studies have addressed the importance of assessing the cardiovascular fitness before resuming sexual activity 20 and to avoid the concurrent use of sildenafil with nitrate, which might induce fatal hypotension. 21 If appropriately used, sildenafil is considered to be a very safe agent.
However, during chart review in our study, 0.66% (11/1158) of the subjects were found to have concomitant prescription of nitrate and sildenafil. Since ischemic heart disease and ED share the same risk factors, it is not uncommon for subjects to have both diseases. Before prescribing sildenafil or nitrate, physicians should screen for the existence of each. On the other hand, subjects using sildenafil or nitrate should be well informed of this absolute contraindication and should also inform their visiting doctors about the use of these drugs.
It was reported that 39.4% of sildenafil prescriptions were by urologists in the US. 22 In contrast, urologists constituted 91.1% of sildenafil prescribers at our institution in Taiwan. Since ED is associated with multiple factors, more than 40% of our subjects sustained various chronic diseases that required long-term medication and regular followup. The responsible physicians should have more chances to treat their ED together with chronic diseases. Several possible reasons account for their reluctance to treat ED. The most likely reasons are that other physicians are not familiar with the diagnosis and treatment of ED or are still not convinced of the importance of treating their patients with ED. Moreover, they are hampered by time constraint in busy daily practice.
Conclusion
Sildenafil is effective in the treatment of ED with mild AE in clinical practice. Unlike in clinical trials or prospective clinical practice-based studies, there were shortfalls in daily practice, such as lacking dose titration, less follow-up visits and inadequate attempts before giving up. There were still a few prescriptions of sildenafil coming from physicians of specialties other than urology. In the era after the launch of sildenafil, ED has become a medical disease and an easier disease to treat. Continuous education to patients and physicians about ED and the new treatment modality remains a priority.
